7
ALL7
Bright Peak TherapeuticsYear
7
ALL2
20241
20223
20211
2020DEALS // DEV.
7
ALL5
Deals2
DevelopmentsCountry
7
ALL1
CHINA6
SWITZERLAND7
ALL1
Ajinomoto Bio-Pharma1
Johnson & Johnson1
Livzon Pharmaceutical Group2
Not Applicable1
RA Capital1
Ridgeline Therapeutics DiscoveryTherapeutic Area
7
ALL7
OncologyStudy Phase
7
ALL2
Phase I/ Phase II1
Phase I3
IND Enabling1
UndisclosedDeal Type
5
ALL1
Collaboration1
Licensing Agreement1
Series A Financing1
Series B Financing1
Series C FinancingProduct Type
7
ALL7
Large moleculeDosage Form
1
ALL1
Intravenous InjectionLead Product
7
ALL2
BPT-1432
BPT5671
IL-2 conjugates1
Immunocytokines1
LZM009Target
4
ALL1
CD25 receptor1
IL-21
IL-2 receptor alpha1
PD-1Lead Product(s) : BPT567
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bright Peak Doses First Patient in Phase 1/2a Trial of BPT567 Immunoconjugate
Details : BPT567, is a bifunctional PD1-IL18 immunoconjugate aimed at activating and enhancing immune responses directly within the tumor microenvironment.
Product Name : BPT567
Product Type : Large molecule
Upfront Cash : Not Applicable
October 17, 2024
Lead Product(s) : BPT567
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BPT567
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Johnson & Johnson
Deal Size : $90.0 million
Deal Type : Series C Financing
Bright Peak Therapeutics Announces $90 Million in Series C Financing for PD1-IL18
Details : The proceeds from the Series C financing will be used to advance the Bright Peak Therapeutics lead product BPT567 into a clinical trial for the treatment of neoplasms.
Product Name : BPT567
Product Type : Large molecule
Upfront Cash : Undisclosed
June 11, 2024
Lead Product(s) : BPT567
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Johnson & Johnson
Deal Size : $90.0 million
Deal Type : Series C Financing
Lead Product(s) : BPT-143
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BPT-143, full-length, folded and PEGylated protein demonstrated power of protein synthesis platform to engineer pleiotropic native cytokines into optimized therapeutics and exploiting technology to develop pipeline of novel designer cytokines and multi-m...
Product Name : BPT-143
Product Type : Large molecule
Upfront Cash : Not Applicable
April 04, 2022
Lead Product(s) : BPT-143
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LZM009
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Livzon Pharmaceutical Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the license agreement, Bright Peak will receive the right to develop, manufacture and commercialize PD-1 ICs, including LZM009 on a worldwide basis while Livzon retains certain rights of first negotiation to obtain exclusivity in the g...
Product Name : LZM009
Product Type : Large molecule
Upfront Cash : Undisclosed
November 16, 2021
Lead Product(s) : LZM009
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Livzon Pharmaceutical Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BPT-143
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : RA Capital
Deal Size : $107.0 million
Deal Type : Series B Financing
Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors
Details : BPT-143 is an enhanced, half-life extended, IL-2 cytokine that uses small modifications to amino acid side chains to block binding to IL-2 receptor alpha, and enhance binding to IL-2 receptor beta.
Product Name : BPT-143
Product Type : Large molecule
Upfront Cash : Undisclosed
June 10, 2021
Lead Product(s) : BPT-143
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : RA Capital
Deal Size : $107.0 million
Deal Type : Series B Financing
Lead Product(s) : Immunocytokines
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Ajinomoto Bio-Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the collaboration and license agreement with Ajinomoto Co., the AJICAP® technology will be used to conjugate Bright Peak’s enhanced cytokines as payloads to certain antibodies, creating novel and proprietary Bright Peak Immunocytokines.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Undisclosed
March 25, 2021
Lead Product(s) : Immunocytokines
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Ajinomoto Bio-Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : IL-2 conjugates
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Ridgeline Therapeutics Discovery
Deal Size : $35.0 million
Deal Type : Series A Financing
Versant Ventures Launches Bright Peak Therapeutics
Details : Bright Peak’s technology platform allows a wide range of proteins to be chemically assembled de novo. The company has validated the platform by creating a portfolio of designer cytokines with the potential to be advanced as novel immune-oncology therap...
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : IL-2 conjugates
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Ridgeline Therapeutics Discovery
Deal Size : $35.0 million
Deal Type : Series A Financing